 CohBar Inc NASDAQ: CWBR has updated the timing for releasing Phase 1a1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis NASH and obesity. The process of data entry and final validation, which must be concluded before database lock, is ongoing. 